HistoSonics, an innovative medical technology company, is preparing to take a crucial new step by considering a public offering in the United States. Supported by the giant Johnson & Johnson, this company is revolutionizing the field with its non-invasive platform and sound beam therapy. Discussions with investment banks are multiplying, with the goal of raising several hundred million dollars, while aiming for a valuation of several billion during this potential public offering.

HistoSonics, a company specializing in medical devices, develops non-invasive solutions based on sound beam therapy. Supported by the Johnson & Johnson venture capital fund, the company is considering a public offering in the United States in the near future. Currently being evaluated to raise several hundred million dollars, HistoSonics aspires to a valuation of several billion during this operation, while collaborating with investment banks.

HistoSonics and its IPO Project

HistoSonics, an innovative company in the medical device field, has recently caught the attention of investors by considering a public offering in the United States. Supported by the Johnson & Johnson venture capital fund, HistoSonics is developing therapy technologies that could revolutionize tumor treatment. The company relies on the science of histotripsy, a non-invasive method using targeted ultrasound to destroy tumoral tissue. This promising approach could transform how surgical interventions are performed in the coming years.

A Significant Fundraising

HistoSonics recently announced that it successfully closed a fundraising round of 40 million dollars in a series C-1 financing round, reflecting the enthusiasm of investors for its innovative solutions. This oversubscribed financing was led by Yonjin Venture, LLC, which specializes in early and mid-stage life sciences companies. This amount will be used to accelerate technology development and support the company’s commercial growth in the U.S. market and internationally, highlighting HistoSonics’ growing importance in the medical sector.

Towards an Impressive Valuation

The company anticipates a valuation of several billion dollars at its IPO, leveraging its unique expertise in non-invasive treatments. Considering the discussions that have taken place with investment banks, HistoSonics projects to achieve significant revenue, potentially reaching several hundred million dollars through the sale of its shares. As the technology continues to prove itself, HistoSonics seems poised to position itself as a leader in the medical device field, offering solutions that address critical medical needs.